Target intelligence / Profile preview

Mucin (MUC) (MUC)

Target
MUC
Molecular classification
Glycoprotein, Extracellular matrix component
01

Overview

Respiratory mucus is a complex viscoelastic hydrogel primarily composed of high-molecular-weight glycoproteins known as mucins, which were historically characterized in pharmacological literature as mucopolysaccharide fibers (Thornton & Sheehan, 2004). These fibers form an extensive cross-linked network through disulfide bonds and non-covalent interactions, serving as a critical physical barrier that traps pathogens and particulates for removal via mucociliary clearance (Balsamo et al., 2010). In chronic respiratory conditions such as COPD, asthma, and cystic fibrosis, the overproduction and altered chemical structure of these fibers lead to mucus hyperviscosity and impaired clearance, contributing to airway obstruction and recurrent infections (Fahy & Dickey, 2010). Therapeutic agents known as mucolytics target these fibers to restore normal mucus rheology; for example, N-acetylcysteine reduces viscosity by cleaving disulfide bridges, while secretolytic agents like bromhexine and ambroxol are described as fragmenting the mucopolysaccharide chains and stimulating surfactant production (Zanasi et al., 2017). Understanding the molecular architecture of these fibers is essential for developing treatments that can effectively liquefy pathological mucus without compromising its protective functions (StatPearls, 2023).

Other names
Mucopolysaccharide fibersAcid mucopolysaccharidesMucus glycoproteinsMucin networkRespiratory mucus gelMUC5ACMUC5B
02

Mechanism of action

Mucolytics reduce the viscosity of respiratory secretions by depolymerizing the mucin network; this is achieved through the cleavage of disulfide bonds (e.g., N-acetylcysteine) or the fragmentation of the carbohydrate-rich mucopolysaccharide chains (e.g., bromhexine) (Zanasi et al., 2017; StatPearls, 2023).

03

Biological functions

Mucociliary clearancePhysical barrierPathogen trappingAirway hydration
04

Disease associations

Chronic obstructive pulmonary diseaseCystic fibrosisAsthmaBronchitisBronchiectasisRespiratory tract infection
05

Safety considerations

Bronchospasm (particularly with inhaled administration)Gastrointestinal irritationDisruption of the protective gastric mucus barrierNausea
06

Interacting drugs

Bromhexine

5 more in the full profile.

07

Biomarkers

Sputum viscosityMUC5AC expression levelsMUC5B expression levelsMucociliary clearance rate

Beyond the preview

Go deeper on Mucin (MUC) (MUC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucin (MUC) (MUC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call